Remarks

Claims 1-19, 23, 37, 41, 46, 57, 60, 67, 72, 73 and 93 were previously pending. By this amendment claims 8-16, 19, 23, 37, 41, 46, 57, 60, 67, 72, 73, and 93 are canceled without prejudice or disclaimer. No new matter has been introduced. Upon entry of this amendment, claims 1-7 and 17-18 remain currently pending.

The Examiner has required restriction among:

Group I – Claims 1-6, 7 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering PSA1 and an anti-allergy medicament;

Group II – Claims 1-6, 8 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering PSA2 and an anti-allergy medicament;

Group III – Claims 1-6, 9 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering PSB and an anti-allergy medicament;

Group IV – Claims 1-6, 10 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering Streptococcus pneumoniae capsular polysaccharide 1 (CP1) and an anti-allergy medicament;

Group V – Claims 1-6, 11 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering de-N-acetylated Salmonella typhi Vi antigen and an anti-allergy medicament;

Group VI – Claims 1-5, 12 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering aminated pectin and an anti-allergy medicament;

Group VII – Claims 1-5, 13 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering synthetic peptidoglycan Compound 15 and an anti-allergy medicament;

Group VIII – Claims 1-4, 14 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering a peptide an anti-allergy medicament;

Group IX – Claims 1-4, 15 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering a polymer wherein the polymer is $(K\text{-}D)_n$ wherein n is an integer between 10 and 100 inclusive and an anti-allergy medicament;

Group X – Claims 1-4, 16 and 17-18, drawn to a method for treating an allergic condition other than asthma in a subject comprising administering a polymer wherein the polymer is $(K\text{-}Xaa)_m\text{-}D)_n$ wherein each Xaa is independently any neutral amino acid, m is an integer between 0 and 8, inclusive and n is an integer between 10 and 100 inclusive and an anti-allergy medicament;

Group XI – Claim 19, drawn to a method for treating an allergic condition associated with an identified allergen comprising exposing the subject to the identified allergen and administrating an isolated polymer including repeating units of a charge motif characteristic of B. fragilis polysaccharide A (PSA);

Group XII – Claim 23, drawn to a method for treating asthma in a subject comprising administering an isolated polymer comprising repeating units of a charge motif characteristic of B fragilis polysaccharide A (PSA);

Group XIII – Claim 37, drawn to a method for treating a subject having asthma associated with an identified allergen comprising exposing the subject to the identified allergen and administering to the subject a polymer that includes repeating units of a charge motif characteristic of B. fragilis polysaccharide A (PSA);

Group XIV – Claim 41, drawn to a method for inducing IL-10 production comprising isolating a T regulatory cell and contacting the cell with an isolated polymer that includes repeating units of a charge motif characteristic of B. fragilis polysaccharide A (PSA);

Group XV – Claim 46, a method for inducing expression of inducible costimulatory molecule (ICOS) on a CD4+ cell comprising contacting a CD4+ cell with an effective amount of an isolated polymer to induce expression of ICOS on the CD4+ cell wherein the polymer comprises repeating units of charge motif characteristic of B. fragilis polysaccharide A (PSA) and measuring an increased ICOS expression on the CD4+ cell;

Group XVI – Claims 57 and 60, drawn to a method for inducing proliferation of T regulatory cells comprising isolating population of T cells and contacting the population with an isolated polymer including repeating units of charge motif characteristic of B. fragilis polysaccharide A (PSA);

Group XVII – Claim 67, drawn to a method for inhibiting an antigen-specific immune response in a subject wherein the antigen-specific response is other than an allergic condition or asthma comprising administering to a subject an antigen and an isolated polymer that includes repeating units of charge motif characteristic of B. fragilis polysaccharide A (PSA); and

Group XVIII – Claims 72-73 and 93, drawn to a composition comprising a conjugate comprising an antigen and a polymer having repeating units of charge motif characteristic of B. fragilis polysaccharide A (PSA), an aerosol formulation of the polymer and an aerosol delivery system.

In response to the Restriction Requirement, Applicant has elected the claims of Group I for current examination. Group I includes claims 1-6, 7, and 17-18.

Upon election of Group I, the Examiner further required Applicant to elect a single disclosed polymer species with a specified structure including a specified negatively charged moiety selected from carboxyl, phosphate, phosphonate, sulfate and sulfonate, and, further, to elect a single anti-allergy medicament as set forth in claim 17.

In accord with the present election of Group I, Applicant has elected PSA1 as a polymer, carboxyl as a negatively charged moiety, and antihistamine as an anti-allergy medicament.

Applicant believes the claims are in condition for allowance. An early and favorable response is solicited.

Respectfully submitted,

By _____

Alan W. Steele, M.D., Ph.D.
Registration No.: 45,128
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
(617) 646-8000

Dated: February 16, 2007
WGS Date: 2/21/2007
Attorney Docket No. B0801.70280US01